Basilea Pharmaceutica's revenue is forecast to decline at 2% per annum while its annual earnings are expected to grow at 6.2% per year. EPS is expected to grow by 3.1% per annum. Return on equity is forecast to be 11.2% in 3 years.
Key information
6.2%
Earnings growth rate
3.05%
EPS growth rate
Biotechs earnings growth
22.3%
Revenue growth rate
-2.0%
Future return on equity
11.21%
Analyst coverage
Low
Last updated
05 Jun 2026
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
DB:PK5 - Analysts future estimates and past financials data (CHF Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
202
19
N/A
20
2
12/31/2027
267
39
N/A
12
3
12/31/2026
263
53
N/A
59
4
12/31/2025
232
40
59
62
N/A
9/30/2025
234
56
69
71
N/A
6/30/2025
236
73
78
79
N/A
3/31/2025
222
75
75
77
N/A
12/31/2024
209
78
73
74
N/A
9/30/2024
179
38
41
42
N/A
6/30/2024
149
-1
9
10
N/A
3/31/2024
153
5
11
12
N/A
12/31/2023
158
10
13
14
N/A
9/30/2023
166
33
20
22
N/A
6/30/2023
175
56
27
29
N/A
3/31/2023
161
34
16
18
N/A
12/31/2022
148
12
4
7
N/A
9/30/2022
150
6
-2
1
N/A
6/30/2022
152
1
-8
-5
N/A
3/31/2022
150
-3
-20
-18
N/A
12/31/2021
148
-7
-33
-32
N/A
9/30/2021
130
-26
-41
-40
N/A
6/30/2021
112
-45
-50
-48
N/A
3/31/2021
120
-30
-53
-51
N/A
12/31/2020
128
-15
-56
-54
N/A
9/30/2020
134
-6
-55
-53
N/A
6/30/2020
141
3
-53
-52
N/A
3/31/2020
137
-10
-58
-58
N/A
12/31/2019
134
-22
-64
-64
N/A
9/30/2019
135
-23
N/A
-64
N/A
6/30/2019
136
-24
N/A
-64
N/A
3/31/2019
134
-28
N/A
-72
N/A
12/31/2018
133
-31
N/A
-79
N/A
9/30/2018
124
-26
N/A
-42
N/A
6/30/2018
115
-21
N/A
-5
N/A
3/31/2018
108
-20
N/A
7
N/A
12/31/2017
102
-19
N/A
19
N/A
9/30/2017
92
-32
N/A
-19
N/A
6/30/2017
82
-44
N/A
-58
N/A
3/31/2017
74
-48
N/A
-66
N/A
12/31/2016
66
-51
N/A
-75
N/A
9/30/2016
62
-55
N/A
-89
N/A
6/30/2016
58
-59
N/A
-102
N/A
3/31/2016
55
-61
N/A
-85
N/A
12/31/2015
53
-62
N/A
-68
N/A
9/30/2015
50
-57
N/A
-57
N/A
6/30/2015
47
-52
N/A
-46
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PK5's forecast earnings growth (6.2% per year) is above the savings rate (1.9%).
Earnings vs Market: PK5's earnings (6.2% per year) are forecast to grow slower than the German market (17% per year).
High Growth Earnings: PK5's earnings are forecast to grow, but not significantly.
Revenue vs Market: PK5's revenue is expected to decline over the next 3 years (-2% per year).
High Growth Revenue: PK5's revenue is forecast to decline over the next 3 years (-2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PK5's Return on Equity is forecast to be low in 3 years time (11.2%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/17 02:53
End of Day Share Price
2026/06/17 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Basilea Pharmaceutica AG is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.